Back to top
more

The Joint (JYNT)

(Delayed Data from NSDQ)

$17.06 USD

17.06
70,862

+0.61 (3.71%)

Updated May 14, 2024 04:00 PM ET

After-Market: $17.01 -0.05 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (52 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics

by Zacks Equity Research

The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.

Do Options Traders Know Something About The Joint (JYNT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to The Joint (JYNT) stock based on the movements in the options market lately.

Humana (HUM) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 13.04% and 1.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Humana (HUM): Can Its 3.2% Jump Turn into More Strength?

by Zacks Equity Research

Humana (HUM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%

by Zacks Equity Research

The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.

The Joint Corp. (JYNT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -125% and 1.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Humana (HUM) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 17.72% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Centene (CNC) delivered earnings and revenue surprises of 8.93% and 7.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

UnitedHealth (UNH) delivered earnings and revenue surprises of 1.67% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) Buys Northern California Regional Developer Zone

by Zacks Equity Research

The Joint (JYNT) expects the Northern California region to hold 75 clinics, including its right to oversee 56 franchisee clinics.

    Molina (MOH) to Join S&P 500 Driven by Medicare Performance

    by Zacks Equity Research

    Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.

    The Joint Corp. (JYNT) Q4 Earnings Lag Estimates

    by Zacks Equity Research

    The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp

    by Zacks Equity Research

    Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.

    Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?

    by Zacks Equity Research

    In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

    Medtronic (MDT) to Report Q3 Earnings: What's in Store?

    by Zacks Equity Research

    Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.

    The Joint Corp. (JYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

    by Zacks Equity Research

    The Joint Corp. (JYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    What's in Store for Teladoc's (TDOC) Q4 Earnings?

    by Zacks Equity Research

    Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.

    Wall Street Analysts Think The Joint Corp. (JYNT) Could Surge 84%: Read This Before Placing a Bet

    by Zacks Equity Research

    The consensus price target hints at an 84.3% upside potential for The Joint Corp. (JYNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden

    by Zacks Equity Research

    Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.

    Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums

    by Zacks Equity Research

    Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.

    Molina (MOH) Q4 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Merck (MRK) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Humana (HUM) Q4 Earnings Surpass Estimates

    by Zacks Equity Research

    Humana (HUM) delivered earnings and revenue surprises of 0.81% and 0.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will The Joint Corp. (JYNT) Beat Estimates Again in Its Next Earnings Report?

    by Zacks Equity Research

    The Joint Corp. (JYNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    The Joint Corp. (JYNT) Moves 9% Higher: Will This Strength Last?

    by Zacks Equity Research

    The Joint Corp. (JYNT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.